Federal Pharmaceuticals (03933): Tokugu Insulin Liraglutide Injection Application Accepted

Zhitong Financial App News, Federal Pharmaceutical (03933) announced that the Toku Insulin Liraglutide Injection (iDeglira) independently developed by Zhuhai Federal Biomedical Co., Ltd., a wholly-owned subsidiary of the company, has been accepted by the China National Drug Administration for marketing registration. The acceptance number is CXSS2600154. The company is the first company in China to submit an application for marketing registration of German insulin liraglutide biosimilar drugs.

Tokugu insulin liraglutide injection is a long-acting compound hypoglycemic preparation composed of the basic insulin Tokugai insulin (iDeg) and liraglutide, an analogue of human glucagon-like peptide-1 (GLP-1). The two components maintain their respective pharmacokinetic characteristics in the compound formulation. Through complementary advantages and synergy, they break through the limitations of single-drug treatment, achieve stable sugar control around the clock, significantly improve the blood sugar achievement rate, and balance weight management with hypoglycemia risk control to achieve multiple clinical values of “sugar reduction, sugar stabilization, and safe weight control”. Compared with single drugs or combination drugs, this product only requires subcutaneous injection once a day. While improving efficacy and safety, it greatly simplifies the dosage plan, improves long-term compliance, and provides a new, more efficient, safe, and convenient integrated treatment option for type 2 diabetics.

This listing registration application is another important achievement of the company in the field of diabetes treatment. In the future, the company will continue to work on new product research and development, and focus on enhancing competitiveness and creativity in the biomedical industry, deepening the field of chronic disease treatment, serving clinical trials and benefiting patients with better products and better pipelines, which is expected to generate greater benefits for the company and its shareholders.